Successful Treatment of Morphea with Topical Ruxolitinib

Main Article Content

McKenzie A. Dirr
Medical University of South Carolina

Avi Bitterman
Icahn School of Medicine at Mt Sinai, New York, New York

Roudha Al-Dehneem
Icahn School of Medicine at Mt Sinai, New York, New York

Alice B. Gottlieb
Icahn School of Medicine at Mt Sinai, New York, New York

Keywords

Morphea, Localized Scleroderma, Ruxolitinib

References

1. Bolognia J, Schaffer JV, Duncan KO, Ko CJ. Dermatology Essentials. Second edition. Elsevier; 2022.

2. Albuquerque JV, Andriolo BN, Vasconcellos MR, Civile VT, Lyddiatt A, Trevisani VF. Interventions for morphea. Cochrane Database Syst Rev. 2019;7(7):CD005027. Published 2019 Jul 16. doi:10.1002/14651858.CD005027.pub5

3. Kurzinski K, Torok KS. Cytokine profiles in localized scleroderma and relationship to clinical features. Cytokine. 2011;55(2):157-164. doi:10.1016/j.cyto.2011.04.001

4. Traidl S, Freimooser S, Werfel T. Janus kinase inhibitors for the therapy of atopic dermatitis. Allergol Select. 2021 Aug 27;5:293-304. doi: 10.5414/ALX02272E. PMID: 34532638; PMCID: PMC8439108.

5. Elli EM, Baratè C, Mendicino F, Palandri F, Palumbo GA. Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib. Front Oncol. 2019 Nov 7;9:1186. doi: 10.3389/fonc.2019.01186. PMID: 31788449; PMCID: PMC6854013.

Article Sidebar

PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.2.19

Article Details

How to Cite
Dirr, M. A. ., Bitterman, A. ., Al-Dehneem, R., & Gottlieb, A. B. (2023). Successful Treatment of Morphea with Topical Ruxolitinib . SKIN The Journal of Cutaneous Medicine, 7(2), 747–749. https://doi.org/10.25251/skin.7.2.19
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
SKINmages: Clinical Images in Dermatology
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.